[HTML][HTML] Therapeutic Drug Monitoring of Direct Oral Anticoagulants in Patients with Extremely Low and High Body Weight—Pilot Study
Ł Wołowiec, M Kusiak, J Budzyński… - Journal of Clinical …, 2023 - mdpi.com
Phase III clinical trials for individual direct oral anticoagulants (DOACs) contained a limited
representation of subjects with abnormal body weight, which were mostly limited to a BMI> …
representation of subjects with abnormal body weight, which were mostly limited to a BMI> …
Therapeutic Drug Monitoring of Direct Oral Anticoagulants in Patients with Extremely Low and High Body Weight-Pilot Study
Ł Wołowiec, M Kusiak, J Budzyński… - Journal of clinical …, 2023 - pubmed.ncbi.nlm.nih.gov
Phase III clinical trials for individual direct oral anticoagulants (DOACs) contained a limited
representation of subjects with abnormal body weight, which were mostly limited to a BMI> …
representation of subjects with abnormal body weight, which were mostly limited to a BMI> …
Therapeutic Drug Monitoring of Direct Oral Anticoagulants in Patients with Extremely Low and High Body Weight—Pilot Study.
Ł Wołowiec, M Kusiak, J Budzyński… - Journal of Clinical …, 2023 - search.ebscohost.com
Phase III clinical trials for individual direct oral anticoagulants (DOACs) contained a limited
representation of subjects with abnormal body weight, which were mostly limited to a BMI …
representation of subjects with abnormal body weight, which were mostly limited to a BMI …
[HTML][HTML] Therapeutic Drug Monitoring of Direct Oral Anticoagulants in Patients with Extremely Low and High Body Weight—Pilot Study
Ł Wołowiec, M Kusiak, J Budzyński… - Journal of Clinical …, 2023 - ncbi.nlm.nih.gov
Phase III clinical trials for individual direct oral anticoagulants (DOACs) contained a limited
representation of subjects with abnormal body weight, which were mostly limited to a BMI> …
representation of subjects with abnormal body weight, which were mostly limited to a BMI> …
Therapeutic Drug Monitoring of Direct Oral Anticoagulants in Patients with Extremely Low and High Body Weight—Pilot Study
Ł Wołowiec, M Kusiak, J Budzyński… - Journal of Clinical …, 2023 - search.proquest.com
Phase III clinical trials for individual direct oral anticoagulants (DOACs) contained a limited
representation of subjects with abnormal body weight, which were mostly limited to a BMI> …
representation of subjects with abnormal body weight, which were mostly limited to a BMI> …
Therapeutic Drug Monitoring of Direct Oral Anticoagulants in Patients with Extremely Low and High Body Weight-Pilot Study.
Ł Wołowiec, M Kusiak, J Budzyński… - Journal of Clinical …, 2023 - europepmc.org
Therapeutic Drug Monitoring of Direct Oral Anticoagulants in Patients with Extremely Low and
High Body Weight-Pilot Study. - Abstract - Europe PMC Sign in | Create an account https://orcid.org …
High Body Weight-Pilot Study. - Abstract - Europe PMC Sign in | Create an account https://orcid.org …